Meeting
Abstract Number: 144
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant [...]
Abstract Number: 145
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: Venous thromboembolism (VTE) in hospitalized medically ill patients is a leading preventable cause of morbidity and mortality in the United States. About half of VTE events occur following discontinuation of standard-duration in-hospital prophylaxis and hospital discharge. The APEX study evaluated Betrixaban for in-hospital to home VTE prophylaxis and is the first FDA approved anticoagulant [...]
Abstract Number: 221
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Background: The venous thromboembolism (VTE) rate in patients with current or recent hospitalization is 330/100,000 person-year vs. 8/100,000 in outpatients. Hence, hospitalists often assess risk and pursue a diagnosis of VTE in their patients. Lower extremity (LE) DVT risk prediction tools such as the Wells score perform poorly on inpatients and hospitalist specific guidelines for [...]
